Medicinal Cannabis in Australia: A Complete Guide to Access, Safety & Clinical Use

Medicinal cannabis has become a prominent part of therapeutic conversations in Australia — offering potential relief for a range of conditions while operating within a tightly regulated framework. This guide provides a clear, compliant, and clinically informed overview of how medicinal cannabis works in Australia, how patients can access it, and what safety considerations both clinicians and patients need to understand. Relevant regulatory guidance from the Therapeutic Goods Administration (TGA) has been incorporated throughout to ensure accuracy and alignment with Australian best practice. 

What Is Medicinal Cannabis?

Medicinal cannabis refers to cannabis‑based products used under medical supervision to treat specific health conditions. These products often contain cannabinoids — chemical compounds such as tetrahydrocannabinol (THC) and cannabidiol (CBD) — which interact with the body’s endocannabinoid system. THC is associated with psychoactive effects, while CBD is non‑intoxicating and more widely studied for certain therapeutic uses. 

It’s important to note that medicinal cannabis differs substantially from recreational cannabis and must be prescribed legally through approved medical pathways. 

Australia’s Regulatory Framework for Medicinal Cannabis

Therapeutic Goods Administration (TGA)

The TGA is the Commonwealth regulator responsible for overseeing the supply, access and quality aspects of medicinal cannabis in Australia. The TGA regulates medicinal cannabis products as therapeutic goods and provides guidance documents to assist clinicians and patients to navigate appropriate use. 

Key points about TGA regulation: 

• Most medicinal cannabis products are considered unapproved therapeutic goods because they haven’t been fully evaluated for safety, quality or effectiveness under standard TGA processes. 

• Registered medical practitioners must use special access pathways to prescribe these products, as they are not usually listed on the Australian Register of Therapeutic Goods (ARTG).  

Other Regulatory Bodies

In addition to the TGA, prescribers are bound by professional standards set by bodies like the Australian Health Practitioner Regulation Agency (AHPRA), which recently reinforced guidelines that remind clinicians that medicinal cannabis should be treated with similar rigour and caution as other controlled medicines. 

How to Access Medicinal Cannabis in Australia

To legally access medicinal cannabis, patients must work through a registered health professional who applies via regulated pathways: 

1. Special Access Scheme (SAS‑B)

Under SAS‑B, a clinician can apply to the TGA to prescribe an unapproved medicinal cannabis product for a specific patient based on clinical justification. Each application must demonstrate why authorised treatments are unsuitable and outline monitoring strategies. 

2. Authorised Prescriber (AP) Scheme

Under the AP scheme, a clinician can become authorised to prescribe medicinal cannabis to a group of patients with similar conditions over time without submitting individual SAS‑B applications — provided they meet specific ethical or specialist criteria. 

These regulated access pathways ensure that prescribing is clinically justified and monitored rather than ad‑hoc or unsupervised.  

Conditions & Evidence for Clinical Use

Available Evidence

The TGA’s clinical guidance emphasises that evidence for many medicinal cannabis uses remains limited and heterogeneous. This means strong, high‑quality clinical trials are lacking for most conditions, and decisions must be made with careful clinical judgement.

Doctors are guided to use a “start low, go slow” approach to dosing due to variable effects and incomplete evidence on optimal regimens.

Conditions Where Medicinal Cannabis May Be Used

Some areas where medicinal cannabis products are sometimes prescribed include:

• Chronic non‑cancer pain

• Nausea and vomiting associated with chemotherapy

• Muscle spasticity in multiple sclerosis

• Treatment‑resistant epilepsy (e.g., with CBD products in specific syndromes)

It’s important to note that two products, nabiximols and Epidyolex (CBD), are among the few that are formally approved and listed on the ARTG for specific indications. 

Safety, Risks & Clinical Monitoring

Medicinal cannabis is treated like other prescription medicines, especially those with potential for misuse or side effects. Most products contain THC, which is a Schedule 8 controlled medicine, meaning they are subject to tight prescribing controls.

Side Effects & Interactions

Common side effects can include dizziness, sedation, appetite changes, and cognitive effects. There can also be interactions with other medications — making clinicians’ oversight crucial.

Quality Standards

Products must comply with rigorous manufacturing standards, known as TGO 93, which establish quality requirements for medicinal cannabis products.

Real‑World Safety Issues

Concerns have been raised in Australia about inappropriate prescribing and the rapid rise in medicinal cannabis use, prompting regulators to stress careful assessment and documentation to protect patients and support appropriate clinical use.

Patient Experience: From Consultation to Treatment

Accessing medicinal cannabis typically starts with an in‑depth consultation with a clinician who evaluates your medical history, symptoms, and treatment goals. For many Australians, including those who may find it hard to see a specialist, a medicinal cannabis clinic in Australia, especially one offering telehealth services, can help coordinate assessment, TGA approval and ongoing follow‑up under medical supervision.

Because products are not subsidised under the Pharmaceutical Benefits Scheme (PBS), costs vary and are discussed on a case‑by‑case basis with your health provider.

Challenges & the Future of Medicinal Cannabis in Australia

Although medicinal cannabis offers promise, the regulatory landscape continues evolving. Barriers such as clinician discomfort with prescribing due to limited evidence, administrative requirements, and variable patient access remain under review by health authorities. 

There’s a strong focus on expanding education for GPs and improving the evidence generation to support safe, evidence‑based use. 

Conclusion: Safe, Informed, Compliant Use

Medicinal cannabis represents an important treatment option for select patients when clinically appropriate and carefully monitored. Australia’s regulatory framework, led by the TGA and supported by professional standards, seeks to balance patient access with safety and quality.

If you’re considering this treatment path, the first step is to have a GP Telehealth Consultation where a qualified clinician can assess your case and determine whether medicinal cannabis might be an appropriate option for you. Providers like 4Uniwell Health can support informed and compliant discussions about your symptoms, current treatments, and next steps — without over‑promotion but with a focus on your health outcomes.